Revisiting the Incidence of Hypercalcemia in Contemporary Diagnoses of Pediatric Patients With Solid Tumors
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.32044 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Felicia Y Ho und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Hypercalcemia, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Hypercalcemia is rarely observed in pediatric patients with cancer. However, rare cases of renal insufficiency and osteoporosis have been reported as severe consequences. Published literature focuses predominantly on hypercalcemia in pediatric hematologic malignancies, precluding causative associations with solid tumor disease histology or tumor characteristics.
Methods
In this retrospective cohort analysis, we identified 39 patients (aged < 21 years) diagnosed and hospitalized with a solid tumor and prolonged hypercalcemia over the span of 25 years at the Dana‐Farber/Boston Children's Cancer and Blood Disorders Center. Hypercalcemia was defined as a sustained serum calcium of at least 11.5 mg/dL for more than 1 week. Disease characteristics, clinical symptoms, management, and outcome were analyzed.
Results
The median age for patients in this cohort was 2.3 years, and the majority of patients had a diagnosis of neuroblastoma, rhabdoid tumor, hepatoblastoma, or rhabdomyosarcoma. The 39 patients experienced 45 episodes of hypercalcemia, with a median peak serum calcium level (corrected for albumin) of 13.1 mg/dL. The median time from tumor diagnosis to a hypercalcemic episode was 5.4 months, suggesting that disease‐directed therapy, tumor progression, or organ dysfunction may have contributed. Peak ionized calcium was not significantly associated with bone or bone marrow involvement, nor with metastatic disease.
Conclusions
This work describes the largest retrospective series of pediatric patients with solid tumors and hypercalcemia to date. Hypercalcemia was most frequently reported for a small subset of diseases, suggesting that disease histology, biology, and the intensive therapeutic interventions required to treat these diseases may be contributing to hypercalcemic risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
- New York University Grossman Long Island School of Medicine, Mineola, New York, USA.
- Department of Pediatrics, Division of Hematology-Oncology, Phramongkutklao Hospital and Phramongkutklao College of Medicine, Bangkok, Thailand.
- Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Felicia Y Ho, Wendy B London, Allison F O'Neill
Zitieren
APA
Ho, F. Y., Alku, D., Monsereenusorn, C., Chen, N., London, W. B., & O'Neill, A. F. (2025). Revisiting the Incidence of Hypercalcemia in Contemporary Diagnoses of Pediatric Patients With Solid Tumors. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.32044
Vancouver
Ho FY, Alku D, Monsereenusorn C, Chen N, London WB, O'Neill AF. Revisiting the Incidence of Hypercalcemia in Contemporary Diagnoses of Pediatric Patients With Solid Tumors. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.32044
BibTeX
@article{Ho2025,
author = {Ho, Felicia Y and Alku, Dajana and Monsereenusorn, Chalinee and Chen, Nan and London, Wendy B and O'Neill, Allison F},
title = {Revisiting the Incidence of Hypercalcemia in Contemporary Diagnoses of Pediatric Patients With Solid Tumors},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.32044}
}
EUVIMED